bluuebunny/crossref_metadata_2025_split huggingface dataset:
Prevalence and correlates of occupational noise-induced hearing loss among workers in the steel industry
Authors: Elshaer Noha , Meleis Dorria , Mohamed Abdelrahman 
Published: June 2023

Abstract
Background
The steel industry is one of the noisiest industries, which can predispose workers to hearing loss. In Egypt, the demand for steel is increasing due to the construction of new infrastructures as bridges, flyover roads, buildings, and towers; however, little is known about the prevalence of occupational noise-induced hearing loss (NIHL) among steel workers. Understanding the distribution of the affected workers is crucial for planning prevention strategies. This study aimed to estimate the prevalence of occupational NIHL among Egyptian steel workers and identify its correlates.

Methods
This study was conducted at two steel factories in Egypt in November 2021. It involved an initial retrospective review of the factory medical records of the latest periodic medical examination conducted on workers from July to September in the year 2021 representing workers’ health status in that year. Then, a case–control approach analysis was carried out. Eligible workers (n = 606) were enrolled and divided into two groups: noise-exposed workers (n = 396) and unexposed workers (n = 210). Univariate and multivariate regression analyses were performed.

Results
Occupational exposure to hazardous A-weighted equivalent noise level (> 85 dB) was associated with higher hearing thresholds at all frequencies (highest at 4 kHz followed by 6 kHz), particularly in younger workers below the age of 40 years. Nearly 71% of noise-exposed workers had hearing impairment, and 47% had NIHL compared with unexposed workers (45.7% and 11.9%, respectively). The probability of NIHL in noise-exposed workers was 6.55 times higher than that in unexposed workers (OR = 6.55, 95%CI = 4.13, 10.40; p < 0.001). In noise-exposed workers, age and tinnitus were independent predictors of hearing thresholds, while tinnitus was found to be an independent predictor of NIHL after adjusting for age and job duration (OR = 2.06, 95%CI = 1.01, 4.20; p = 0.045).

Conclusion
Almost half of noise-exposed workers had NIHL. Tinnitus was found to be an independent predictor of NIHL. Decreasing noise exposure levels in steel plants is recommended to reduce hearing loss. Future research is required to study the effect of tinnitus on audiometry measurements among workers with NIHL.
A joint InSAR-GNSS workflow for correction and selection of interferograms to estimate high-resolution interseismic deformations
Authors: Liu Hongzhi , Xie Lei , Zhao Guoqiang , Ali Eslam , Xu Wenbin 
Published: June 2023

AbstractKnowledge of the spatial distribution of interseismic deformations is essential to better understand earthquake cycles. The existing methods for improving the reliability of the obtained deformations often rely on visual inspection and prior model corrections that are time-consuming, labor-intensive, and do not consider the spatial distribution of interseismic deformations. Interferometric Synthetic Aperture Radar (InSAR) data provides wide-scale coverage for interseismic deformation monitoring over a wide area. However, the interseismic signal featured as millimeter-scale and long-wave deformations is often contaminated with noise. In the present study, a new workflow to correct the interferometric phase and quantitatively select interferograms is proposed to improve the accuracy of interseismic deformation measurements. Initially, the Generic Atmospheric Correction Online Service (GACOS), Intermittent Code for Atmospheric Noise Depression through Iterative Stacking (I-CANDIS), and plate model are combined to correct the atmospheric screen and long-wave ramp phase. Subsequently, the Pearson’s Correlation Coefficient (PCC) between the interferometric phase and the Global Navigation Satellite System (GNSS) constrained interseismic model as well as the STandard Deviation (STD) of the interferometric phase are introduced as criteria to optimize the selection of interferograms. Finally, the intermittent stacking method is used to generate an average velocity map. A comprehensive test using Sentinel-1 images covering the Haiyuan Fault Zone validate the effectiveness of our workflow in measuring interseismic deformations. This demonstrates that the proposed joint InSAR-GNSS workflow can be extended to study the subtle interseismic deformations of major fault systems in Tibet and worldwide.
Growth hormone therapy response in children with short stature
Authors: Gad Amira Ahmed , Shamma Radwa , Elmonem Mohamed A. , Badawi Nora E. , Fawaz Lubna , Hassan Mona Mamdouh 
Published: June 2023

Abstract
Background
Short stature is one of the main causes of children referral to pediatric endocrinologists. Common etiologies include idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA), and idiopathic short stature (ISS).

Objectives
The aim of this study was to assess and compare the response of children with IGHD, ISS, and SGA to growth hormone (GH) therapy.

Methods
This was a mixed cohort study that included 40 children with short stature (classified into IGHD, ISS, and SGA) following up at Diabetes, Endocrine, and Metabolism Pediatric Unit (DEMPU), Cairo University Children’s Hospital. Ages ranged between 3 and 18 years. Recruited cases were evaluated for their 1-year response to GH therapy. In addition to history taking, physical examination, and anthropometric measurements, serum levels of IGF-1 were assayed at recruitment.

Results
Among the 3 groups, height gain (cm/year) was significantly higher in the IGHD group (6.59 cm/year), followed by the ISS (4.63 cm/year) and SGA groups (4.46 cm/year) (p = 0.039). Using the Bang criterion for first-year responsiveness to GH therapy, most cases (30/40, 75%) were considered poor responders.

Conclusion
There is a male predominance in children seeking medical advice for short stature. Starting GH therapy at an older age was associated with poor response. Children with IGHD respond better to GH therapy than those with ISS and SGA.
The phytochemical screening, total cucurbitacin content, and in vitro anti-breast cancer activity of Leucopaxillus gentianeus mushroom
Authors: Kanani Sonal H. , Pandya Devang J. 
Published: June 2023

Abstract
Background
The popular Leucopaxillus gentianeus mushroom contains very high nutrients and bioactive compounds with good anti-breast cancer activity. The til oil extract seems to be the most active in preparation. This study aims to find the best extract using different solvents for extraction, to measure the total cucurbitacin content and anti-breast cancer activity in vitro of til oil extract of leucopaxillus gentianeus.

Result
The dry mushroom material was extracted using continuous hot extraction with til oil, petroleum ether, ethyl acetate, chloroform, methanol, and water of leucopaxillus gentianeus which were used for phytochemical analysis, HPLC method was used for no of phytochemical and anti-breast cancer activity in vitro. The total cucurbitacin content was found based on the HPTLC method. The anti-breast cancer activity was carried out using progesterone and estrogen activity. The number of pecks found during HPLC it is indicated that the list of phytochemical presents in a different extract, also good yield found with til oil extract was 6.8 gm. Progesterone and estrogen inhibited high with til oil extract and cucurbitacin content was found to be 264.00 ng.

Conclusion
The significance of the biotherapeutic effects increases with the number of bioactive components in the preparation. Leucopaxillus gentianeus til oil extract has high cucurbitacin content and strong anti-breast cancer properties.

Graphical abstract
Benign hepatic tumors in childhood: surgical resection and outcomes
Authors: Younes Alaa , Elgendy Ahmed , Fadel Sayed , Elfandy Habiba , Romeih Marwa , Elwakeel Madeeha , Ahmed Gehad 
Published: June 2023

Abstract

Background
Primary hepatic neoplasms in pediatric age are rare entities. Clinical and survival data in children with benign liver tumors who were treated by surgery are still negligible. We aimed to present a tertiary oncological center experience regarding surgical management and outcomes of pediatric benign hepatic tumors.

Material and methods
A retrospective chart review was performed including all children with benign liver tumors who were surgically managed at our institution from January 2014 to January 2022. Patients’ demographics, presentations, imaging scans, pathological subtypes, operative details, complications that happened, and overall outcomes were discussed.

Results
One-hundred ninety-three children with liver tumors were referred to our center, and 28 of them had benign tumors (14.5%). Ten patients were managed by medical therapy (all were IHH/hemangiomas), and the remaining 18 were treated by surgery. Of the 18 patients; there were 10 females (55.5%), and the median age at diagnosis was 24 months (range: 5–108 months). Palpable abdominal mass was the main symptom in 14 patients (77.8%). Eleven patients (61%) were PRETEXT II, while the remaining 7 (39%) were PRETEXT I. The median tumor size was 10.9 cm (range: 7.2–18 cm). Preoperative biopsy was conducted in 12 patients (66.7%). Seventeen patients had primary resection, while the remaining child with IHH/hemangioma underwent delayed surgery. Twelve cases had segmental resection or sectionectomy, and hemihepatectomy was performed in the remaining six. The resection rate of benign tumors versus all liver resections at our center during the study period was 12% (18/151). There were no intraoperative complications encountered in any patient. Only one patient developed biliary leakage on the 5th postoperative day which was managed conservatively. At a median follow-up time of 40 months, there were no deaths or recurrences among the included patients.

Conclusions
Surgical resection is the principal modality of management for the majority of pediatric benign liver tumors, which constituted 12% of our hepatic resection rate. Complete excision with negative margins can be performed without significant morbidity for such tumors, and it achieves excellent clinical and long-term oncological outcomes.
Isolated anterior mitral valve leaflet cleft repair with minimally invasive cardiac surgery using ORBEYETM
Authors: Hayama Masato , Sumi Mizuki , Amako Mau , Eishi Kiyoyuki , Wada Hideichi 
Published: June 2023

AbstractThe cleft mitral valve leaflet is a common cause of congenital mitral regurgitation and is most often associated with other congenital heart defects, usually endocardial cushion defects. Cases in which cleft mitral valve leaflet is found without an associated defect are called isolated mitral valve clefts. We report a case of mitral valve repair for severe MR due to an isolated cleft with minimally invasive cardiac surgery using ORBEYETM in a 16-year-old male patient. Mitral regurgitation caused due to a defect in the anterior leaflet of the isolated mitral valve was observed on echocardiography. Minimally invasive cardiac surgery was performed using ORBEYETM, a newly developed surgical microscope, and the cleft was closed using interrupted sutures. The postoperative course was uneventful, with minimal mitral regurgitation observed. Therefore, early intervention should be considered for severe mitral regurgitation due to a mitral valve leaflet cleft.
Staged definitive repair for pulmonary atresia and ventricular septal defect 40 years after palliative surgery: a case report
Authors: Ebuoka Noriyoshi , Ando Norihiro , Asai Hidetsugu , Kato Nobuyasu , Tachibana Tsuyoshi , Wakasa Satoru 
Published: June 2023

AbstractWe present a very rare case of pulmonary atresia and ventricular septal defect with staged definitive repair more than 40 years after palliative surgery. The patient, a 43-year-old male, had undergone a Waterston operation at the age of one and had been untreated since then. Two years ago, he underwent an urgent surgery for impending rupture of a huge pulmonary artery aneurysm. Then, after evaluation of cardiac and pulmonary functions, a definitive repair was performed concomitantly with aortic root replacement for the dilated aortic root. He was discharged uneventfully and received ambulatory care 5 years after surgery.
Treatment of focal anaplastic Wilms tumor (FAWT): A report from the Children’s Oncology Group (COG) AREN0321 and AREN03B2 studies.
Authors: Armstrong Amy E. , Daw Najat C. , Renfro Lindsay A. , Geller James I. , Kalapurakal John A. , Khanna Geetika , Paulino Arnold , Perlman Elizabeth J. , Ehrlich Peter F. , Gow Kenneth W. , Warwick Anne B. , Grundy Paul E. , Fernandez Conrad V. , Mullen Elizabeth A. , Dome Jeffrey ,   on behalf of AREN0321 and AREN03B2 Study Committees
Published: June 2023

10005 Background: FAWT represents tumors with circumscribed small areas of anaplastic nuclear changes confined to the kidney within an otherwise favorable histology WT. In National Wilms Tumor Study-5, patients with stage I FAWT treated with vincristine and dactinomycin (VA) without flank radiation had 4-year event-free survival (EFS) and overall survival (OS) of 67.5% and 88.9%, respectively. Patients with stage II-IV FAWT were treated with VA plus doxorubicin and radiation (DD4A). Of the 20 patients with stage II-III FAWT, 4 had a relapse and 3 died. The 4-year EFS and OS for stage IV FAWT/upfront nephrectomy were 61.4% and 71.6%, respectively. The COG AREN0321 study evaluated whether intensifying therapy for stage I and IV FAWT would improve survival of these patients. Methods: Tumor histology and stage were confirmed for all patients by real-time central pathology, surgery, and radiology review on protocol AREN03B2, the COG renal tumor classification, biology, and banking study. Patients then enrolled on AREN0321 with stage I-III FAWT received DD4A and those with stage IV FAWT received vincristine, doxorubicin, cyclophosphamide, carboplatin and etoposide with radiation (UH-1). We analyzed outcomes of patients with FAWT treated on AREN0321 and those enrolled only on AREN03B2 who received the same chemotherapy regimens. Results: A total of 46 patients (25 AREN0321 and 21 AREN03B2) were included in the analyses. Of the 25 AREN0321 patients, 17 (68%) had upfront nephrectomy and all 25 received radiation. Of the 5 AREN0321 patients with stage IV FAWT, 4 had metastasis to lung and 1 to lung and liver. Of the 21 AREN03B2 patients, 19 (90%) had upfront nephrectomy and 17 (81%) reported receiving radiation. The 2 AREN03B2 stage IV patients had lung only metastases. The 4-year EFS and OS are displayed in the table below. No events occurred in stage I-II AREN0321 patients nor in any AREN03B2 patients. Of 10 patients with stage III FAWT on AREN0321, 3 had a relapse. None of the 7 stage IV FAWT patients who received UH-1 had a relapse, but one patient died due to toxicity. Conclusions: Patients with stage I and II FAWT had outstanding survival when treated with DD4A and radiation. Intensification of therapy may be warranted for stage III FAWT and appears to have improved patient survival for stage IV FAWT but with increased risk of toxicity. Strategies to alleviate toxicity of UH-1 therapy have been incorporated into the ongoing COG trial for high-risk patients. Clinical trial information: NCT00335556 . [Table: see text]
Medicaid enrollment changes among U.S. adult survivors of childhood cancer following medicaid expansion: A report from the Childhood Cancer Survivor Study (CCSS).
Authors: Ji Xu , Hu Xin , Mertens Ann C. , Leisenring Wendy M. , Nathan Paul C. , Armstrong Gregory T. , Castellino Sharon M. , Kirchhoff Anne C. 
Published: June 2023

10011 Background: Little is known about whether Medicaid expansion under the Affordable Care Act (ACA) affected insurance coverage among adult survivors of childhood cancer, a population at high-risk for poor health outcome. We addressed this gap by evaluating the association between ACA Medicaid expansion and Medicaid enrollment among participants in the Childhood Cancer Survivor Study (CCSS). Methods: The CCSS cohort of 5-year survivors of childhood cancer was linked to administrative Medicaid insurance data in 2010-2016. We identified 13,895 adult survivors (aged 18-64 years) diagnosed with cancer under age 21 and between 1970 and 1999. Outcomes included (1) percentage with any Medicaid enrollment by year; and (2) Medicaid-covered days (number of days when a survivor was enrolled in Medicaid) during each year. Multivariable difference-in-differences (DD) models were used to examine outcome changes pre vs. post ACA Medicaid expansion, in expansion- vs. non-expansion states, adjusting for age, sex, race/ethnicity, income, education, and chronic conditions. Multivariable models were conducted overall and then stratified by cancer type, race/ethnicity, income, and education. Results: Medicaid enrollment rates increased more in expansion states (17.6% pre-expansion to 24.1% post-expansion) than non-expansion states (16.4% to 16.9%), leading to a net increase in enrollment of 6.6 percentage points (ppt; 95% CI = 5.5-7.7) in the multivariable DD model. Multivariable DD model showed a net increase of 18.4 days (95% CI = 13.8-23.1) in Medicaid-covered days in expansion states relative to non-expansion states. The expansion-associated increase in Medicaid enrollment rates was greatest among survivors of leukemia (multivariable DD estimate: 8.9 ppt, 95% CI = 6.9-11.0) and non-Hodgkin lymphoma (8.0 ppt, 95% CI = 5.0-10.9). Greater increases in Medicaid enrollment were seen in non-Hispanic Black (13.5 ppt, 95% CI = 8.0-19.1) and Hispanic survivors (15.8 ppt, 95% CI = 10.6-21.0) than non-Hispanic White peers (5.1 ppt; 95% CI = 4.0-6.2); in survivors with < $20K household income (11.7 ppt, 95% CI = 8.9-14.4) compared to those with ≥$60K household income (2.9 ppt, 95% CI = 1.6-4.2); and in survivors with high school or lower education (9.3 ppt, 95% CI = 6.9-11.8) compared to those with a college or higher degree (3.9 ppt, 95% CI = 2.6-5.3). Similar patterns were observed across survivor subgroups when examining Medicaid-covered days. Conclusions: We provide the first evidence on increased Medicaid enrollment and longer coverage duration among adult survivors of childhood cancer following Medicaid expansion, with greater increases seen among survivors of underrepresented racial/ethnic populations, those with low socioeconomic status, and high medical need survivors.
Genomic determinants of outcome in acute lymphoblastic leukemia: A Children’s Oncology Group study.
Authors: Chang Ti-Cheng , Chen Wenan , Elsayed Abdelrahman , Pounds Stanley B. , Shago Mary , Rabin Karen R. , Raetz Elizabeth A. , Devidas Meenakshi , Cheng Cheng , Angiolillo Anne L. , Carroll Andrew J. , Heerema Nyla A , Iacobucci Ilaria , Maloney Kelly W. , Pui Ching-Hon , Ramirez Nilsa C. , Hunger Stephen , Wu Gang , Mullighan Charles Grenfell , Loh Mignon L. 
Published: June 2023

10015 Background: While cure rates for childhood acute lymphoblastic leukemia (ALL) exceed 90%, half of relapses arise in those originally classified with standard risk (SR) disease. Methods: We performed genome/transcriptome sequencing of diagnostic and germline samples of children with SR (n=1381) B-ALL or high-risk (HR) B-ALL with favorable cytogenetics ( ETV6: RUNX1 or double trisomy (DT) of chromosomes (chr) 4+10; n=115) to identify predictors of relapse. We used a case-control study to analyze 439 patients who relapsed and 1057 who remained in complete remission for > 5 years. Results: Genomic subtype was associated with relapse. Unbalanced ETV6:RUNX1 translocations were more common than balanced in relapse patients (OR=2.01, CI=1.25-3.20, P=0.002). Conversely, balanced TCF3:PBX1 translocations were more often associated with relapse than unbalanced in TCF3:PBX1 ALL (OR=0.11, CI=0.01-0.50, P=0.003). A striking finding was the high relapse rate in PAX5 altered ALL (57 of 116 cases (49%); OR=3.29, CI=2.16-5.01, P=3.49x10-8). The nature of the heterogeneous PAX5 driver alterations of this subtype influenced relapse risk, with internal PAX5 amplifications and biallelic PAX5 alterations associated with the highest risk. Specific chr gains influenced outcome in hyperdiploid ALL, with gain of chr 10 and disomy of chr 7 associated with favorable outcome (OR=0.27, CI=0.17-0.42, P=8.02x10-10, St Jude Children’s Research Hospital (SJCRH) validation cohort: OR=0.22, CI=0.05-0.80, P=0.009), while disomy of chr 10 and 17 and gain of chr 6 were enriched in patients that relapsed (OR=7.16, CI=2.63-21.51, P=2.19x10-5; SJCRH cohort: OR=21.32, CI=3.62-119.30, P=0.0004). Genomic alterations were also associated with relapse in a subtype-dependent manner, including alterations of INO80 in ETV6:RUNX1, IKZF1 and CREBBP in hyperdiploid, and FHIT in Ph-like ALL. Conclusions: Genetic subtype, aneuploidy patterns, and secondary genomic alterations influence risk of relapse in children otherwise classified with SR ALL, or HR ALL with favorable genetics. Comprehensive genomic analysis is required for optimal risk stratification and treatment allocation, and particularly to study reduction of therapy in the lowest risk patients. [Table: see text]